The antiproliferative activity of all-trans-retinoic acid catabolites and isomers is differentially modulated by liarozole-fumarate in MCF-7 human breast cancer cells

British Journal of Cancer

Volumn 77, Issue 8, 1998, Pages 1229-1235

  Van Heusden, J ^a,b   Wouters, W ^b   Ramaekers, F C S ^a   Krekels, M D W G ^b   Dillen, L ^b   Borgers, M ^a,b   Smets, G ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Catabolite; Isomer; Liarozole fumarate; MCF 7; Metabolism; Retinoic acid

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450; DRUG METABOLITE; LIAROZOLE FUMARATE; RETINOIC ACID; RO 85246; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CATABOLISM; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STEREOISOMERISM;

EID: 0031932905     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.207     Document Type: Article

References (38)

1. Acevedo P and Bertram JS (1995) Liarozole potentiates the cancer chemopreventive activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and β-carotene in 10T1/2 cells. Carcinogenesis 16: 2215-2222
2. Achkar CC, Bentel JM, Boylan JF, Scher HI, Gudas LJ and Miller WH Jr (1994) Differences in the pharmacokinetic properties of orally administered all-transretinoic acid and 9-cis-retinoic acid in the plasma of nude mice. Drug Metab Dis 22: 451-458
3. 3H] retinoic acid after an oral dose in rats. Biochem J 277: 527-531
4. De Coster R, Wouters W, Van Ginckel R, End D, Krekels M, Coene M-C and Bowden C (1992) Experimental studies with liarozole (R 75251): an antitumoral agent which inhibits retinoic acid breakdown. J Steroid Biochem Mol Biol 43: 197-201
5. Dijkman GA, Van Moortselaar RJA, Van Ginckel R, Van Stratum P, Wouters L, Debruyne FMJ, Schalken JA and De Coster R (1994) Antitumoral effects of liarozole in androgen-dependent and -independent R3327-Dunning prostate adenocarcinomas. J Urol 151: 217-222
6. Dolbeare F (1995) Bromodeoxyuridine: a diagnostic tool in biology and medicine. Part I: Historical perspectives, histochemical methods and cell kinetics. Histochem J 27: 339-369
7. Duell EA, Kang S and Voorhees JJ (1996) Retinoic acid isomers applied to human skin in vivo each induce a 4-hydroxylase that inactivates only trans retinoic acid. J Invest Dermatol 106: 316-320
8. Frolik CA, Roberts AB, Tavela TE, Roller PP, Newton DL and Sporn MB (1979) Isolation and identification of 4-hydroxy- and 4-oxoretinoic acid. In vitro metabolites of all-trans-retinoic acid in hamster trachea and liver. Biochemistry 18: 2092-2097
9. Gubler ML and Sherman MI (1990) Metabolism of retinoic acid and retinol by intact cells and cell extracts. Methods Enzymol 189: 525-530
10. Hall AK (1996) Liarozole amplifies retinoid-induced apoptosis in human prostate cancer cells. Anti-Cancer Drugs 7: 312-320
11. Hong WK and Itri LM (1994) Retinoids and human cancer. In The retinoids: Biology, Chemistry and Medicine, Sporn MB, Roberts AB and Goodman DS (eds). pp. 597-630. Raven Press: New York
12. Horwitz KB and McGuire WL (1978) Estrogen control of progesterone receptor in human breast cancer. J Biol Chem 253: 2223-2228
13. Kizaki M, Ueno H, Yamazoe Y, Shimada M, Takayama N, Muto A, Matsushita H, Nakajima H, Morikawa M, Koeffler HP and Ikeda Y (1996) Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood 87: 725-733
14. Krekels MDWG, Zimmerman J, Janssens B, Van Ginckel R, Cools W, Van Hove C, Coene M-C and Wouters W (1996) Analysis of the oxidative catabolism of retinoic acid in rat Dunning R3327G prostate tumors. Prostate 29: 36-41
15. Krekels MDWG, Verhoeven A, van Dun J, Cools W, Van Hove C, Dillen L, Coene M-C and Wouters W (1997) Induction of the oxidative catabolism of retinoic acid in MCF-7 cells. Br J Cancer 75: 1098-1104
16. Lotan R (1980) Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 605: 33-91
17. McCormick AM, Napoli JL, Schnoes HK and DeLuca HF (1978) Isolation and identification of 5,6-epoxy-retinoic acid: A biologically active metabolite of retinoic acid. Biochemistry 17: 4085-4090
18. Mahler C, Verhelst J and Denis L (1993) Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer 71 (suppl.): 1068-1073
19. Moon RC, Mehta RG and Rao KVN (1994) Retinoids and cancer in experimental animals. In The Retinoids: Biology. Chemistry and Medicine, Sporn MB, Roberts AB and Goodman DS (eds). pp. 573-595. Raven Press: New York
20. Muindi JRF, Frankel SR, Miller WHJr, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E and Warrell RPJ (1992) Continuous treatment with all-trans-retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid 'resistance' in patients with acute promyelocytic leukemia. Blood 79: 299-303
21. Roberts AB, Lamb LC and Sporn MB (1980) Metabolism of all-trans-retinoic acid in hamster liver microsomes: oxidation of 4-hydroxy-to 4-keto-retinoic acid. Arch Biochem Biophys 199: 374-383
22. Smets G, Van Ginckel R, Daneels G, Moeremans M, Van Wauwe J, Coene M-C, Ramaekers FCS, Schalken JA, Borgers M and De Coster R (1995) Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid. Prostate 27: 129-140
23. Smith MA, Adamson PC, Balis FM, Feusner J, Aronson L, Murphy RF, Horowitz ME, Reaman G, Hammond GD, Connaghan GD, Hittelman WN and Poplack DG (1992) Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol 10: 1666-1673
24. Stearns ME, Wang M and Fudge K (1993) Liarozole and 13-cis-retinoic acid antiprostatic tumor activity. Cancer Res 53: 3073-3077
25. Urbach J and Rando RR (1994) Isomerization of all-trans-retinoic acid to 9-cis-retinoic acid. Biochem J 299: 459-465
26. Van Ginckel R, De Coster R, Wouters W, Vanherck W, van der Veer R, Goeminne N, Jagers E, Van Cauteren H, Wouters L. Distelmans W and Janssen PAJ (1990) Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats. Prostate 16: 313-323
27. Van heusden J, Borgers M, Ramaekers F, Xhonneux B, Wouters W, De Coster R and Smets G (1996) Liarozole potentiates the all-trans-retinoic acid-induced structural remodelling in human breast carcinoma MCF-7 cells in vitro. Eur J Cell Biol 71: 89-98
28. Van heusden J, de Jong P, Ramaekers F, Bruwiere H, Borgers M and Smets G (1997) Fluorescein-labeled tyramide strongly enhances the detection of low bromodeoxyuridine-incorporation levels. J Histochem Cytochem 45: 315-319
29. Van heusden J, Wouters W, Ramaekers FCS, Krekels MDWG, Dillen L, Borgers M and Smets G (1998) All-trans-retinoic acid metabolites significantly inhibit the proliferation of MCF-7 human breast cancer cells in vitro. Br J Cancer 77: 26-32
30. Van Wauwe JP, Coene M-C, Goosens J, Cools W and Monbaliu J (1990) Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats. J Pharmacol Exp Ther 252: 365-369
31. Van Wauwe J, Van Nyen G, Coene M-C, Stoppie P, Cools W, Goossens J, Borghgraef P and Janssen P (1991) Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther 261: 773-779
32. Van Wauwe J, Coene M-C, Cools W, Goosens J, Lauwers W, Le Jeune L. Van Hove C and Van Nyen G (1994) Liarozole-fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid. Biochem Pharmcol 47: 737-741
33. Warrell RPJr (1993) Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood 82: 1949-1953
34. Warrell RPJr, de The H, Wang ZY and Degos L (1993) Acute promyelocytic leukemia. N Engl J Med 329: 177-189
35. Westarp ME, Westarp MP, Bollag W, Bruynseels J, Biesalski H, Grossmann N and Kornhuber H-H (1994) Effect of six retinoids and retinoic acid catabolic inhibitor liarozole on two glioblastoma cell lines, and in vivo experience in malignant brain tumor patients. In Cancer Treatment - an Update. Banzet P. Holland JF, Khayat D and Weil M (eds). pp.590-598. Springer: Paris
36. White JA, Guo Y-D, Baetz K, Beckett-Jones B, Bonasoro J, Hsu KE, Dilworth FJ, Jones G and Petkovich M (1996) Identification of the retinoic acid-inducible all-trans-retinoic acid 4-hydroxylase. J Biol Chem 271: 29922-29927
37. Wouters W (1994) Retinoid metabolism and its inhibition by liarozole-fumarate. Ann Oncology 5: S45-S47
38. Wouters W, van Dun J, Dillen A, Coene M-C, Cools W and De Coster R (1992) Effects of liarozole, a new antitumor compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. Cancer Res 52: 2841-2846